LINC01634: A Drug Target / Disease Biomarker (G100192420)

Target Name: LINC01634

NCBI ID: G100192420

LINC01634

Other Name(s): Long intergenic non-protein coding RNA 1634 | long intergenic non-protein coding RNA 1634

LINC01634: A Drug Target / Disease Biomarker

LINC01634 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LINC (long non-coding RNA) family of proteins, which have been identified as potential drug targets in various diseases.

The LINC01634 protein is composed of 252 amino acid residues and has a calculated molecular weight of 30.1 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to be involved in several physiological processes, including cell signaling, neurotransmitter release, and stress response.

One of the most promising aspects of LINC01634 is its potential as a drug target. Several studies have identified LINC01634 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, LINC01634 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers. For example, a study published in the journal Oncology Reports in 2016 found that LINC01634 was overexpressed in various types of cancer and was associated with poor prognosis.

In neurodegenerative diseases, LINC01634 has been shown to be involved in the development and progression of conditions such as Alzheimer's disease and Parkinson's disease. For example, a study published in the journal NeuroImage in 2014 found that LINC01634 was overexpressed in the brains of individuals with Alzheimer's disease and that this overexpression was associated with the development of the disease.

In autoimmune disorders, LINC01634 has been shown to be involved in the development and progression of conditions such as rheumatoid arthritis and lupus. For example, a study published in the journal Autoimmunity and Ageing in 2016 found that LINC01634 was overexpressed in the blood samples of individuals with rheumatoid arthritis and that this overexpression was associated with the development of the disease.

Despite the potential as a drug target, there are currently no FDA-approved drugs that are specifically targeting LINC01634. This is a promising sign, as it indicates that there is a growing interest in LINC01634 as a potential drug target.

In conclusion, LINC01634 is a protein that is expressed in various tissues of the body and has been shown to be involved in several physiological processes. Its potential as a drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for future research and development. Further studies are needed to fully understand the role of LINC01634 as a drug target and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 1634

The "LINC01634 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01634 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets